Thyrocare Technologies Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Thyrocare Technologies Ltd trades at ₹550, in a confirmed uptrend and 17 weeks into that stage. That is +11.6% against its own 200-day average. It sits at 73% of a 52-week range of ₹351 to ₹624. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (1 week and counting).

Today the stock is in a confirmed uptrend — week 17 of stage 2, confirmed. At ₹550 it trades +11.6% versus its 200-day average and sits at 73% of its 52-week range (₹351–₹624).

Against the market, two honest reads. Cumulative: over the last 10.3 years the stock moved +164% while the NIFTY 500 moved +245% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (1 week and counting; last ahead the week of 2026-09-04) — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

Story check

Thyrocare Technologies Ltd's story is not scored yet against the markers our research file set on 22 August 2026. Where it sits in its own cycle: MID_EXPANSION. Our fortnightly research layers last read it on 22 August 2026.

Our read, 22 August 2026. The pathology network is converting volume and channel expansion into earnings, while specialty diagnostics remains an option whose delivery timetable has widened.

From the numbers. The current weekly PE is 51.5x, 62nd percentile on the weekly cycle measure, while the normalized valuation verdict is fairly priced. Trailing and normalized PE are nearly the same because current operating margin is…

From the price. Price stage 2, week 17 — above its 200-day line, relative strength rising.

From the research. The pathology network is converting volume and channel expansion into earnings, while specialty diagnostics remains an option whose delivery timetable has widened.

🚨 Where they disagree. The current weekly PE is 51.5x, 62nd percentile on the weekly cycle measure, while the normalized valuation verdict is fairly priced. Trailing and normalized PE are nearly the same because current operating margin is close to the normalized margin; this is not a depressed-earnings inversion. The business is in mid-expansion, so earnings delivery and specialty adoption determine future returns.

What is proven. The pathology network is converting volume and channel expansion into earnings, while specialty diagnostics remains an option whose delivery timetable has widened.

What is not proven yet. The thesis breaks if revenue growth falls below the stated franchise-led framework while operating margin remains below the recent corridor for two reported quarters, because that would show that the existing network is no longer converting volume into operating leverage.

🚨 What would change our mind. The thesis breaks if revenue growth falls below the stated franchise-led framework while operating margin remains below the recent corridor for two reported quarters, because that would show that the existing network is no longer converting volume into operating leverage.

Layer 1 read, 22 August 2026 — KEEP. Best earnings engine here, but every remaining promoter share is pledged behind a parent still selling to repay debt. Revenue grew 24.4% and profit 34.2% in the newest quarter at a 32% operating margin and 35.4% return on capital, and over twelve quarters margin moved 25% to 32% while earnings per share went ₹1.28 to ₹3.28 — real operating leverage, not a re-rating. The timeline flagged promoter selling as unexplained; I found the explanation in its own anchor call, where an analyst states unchallenged that "100% promoter holding is pledged" and the promoter "sold 10% stake in Thyrocare to repay the debt", and management confirms group borrowings of ₹1,050cr with asset sales continuing. Add three guidance promises already scored as missed and a 49.8x multiple with no cushion, and this stays a watch, not a…

What would change Layer 1’s mind. A further fall in promoter holding below about 55% in the next shareholding print, or any disclosure of a pledge invocation, would turn a known overhang into forced supply and take this to DROP regardless of the operating numbers. On the operating side, the September-2026 quarter printing operating margin below 30% (against 33% a year earlier) while revenue growth stays positive would break driver D3 — it would say the laboratory network has stopped converting extra volume into profit, which is…

Layer 2 read, 22 August 2026 — BENCH. Volume growth is real, but the whole diagnostics sector is building capacity without pricing power. Thyrocare's pathology and franchise revenue each grew 26%-27%, and the sector confirms that all callers are growing on volume. The external challenge is supply: capex is +44.84% and CWIP +119.72% with institutions absent, producing CAPACITY_RISK, while six of seven managements carry a delivery flag.

What would change Layer 2’s mind. ADVANCE if the first sector print after this build shows new capacity being absorbed without price cuts, with CWIP growth normalising and a retail price increase sticking.

The test written in advance. The thesis breaks if revenue growth falls below the stated franchise-led framework while operating margin remains below the recent corridor for two reported quarters, because that would show that the existing network is no longer converting volume into operating leverage. — the thesis as written as stated by the next result.

The test written in advance. Management target credibility — Management target credibility Management gives a measurable specialty revenue or adoption update and reconciles it to the stated portfolio target. by the next result.

The test written in advance. Promoter-holding reduction remains unresolved — Promoter-holding reduction remains unresolved A filing identifies the seller, transaction basis and any pledge change, or the next shareholding print stabilizes. by the next result.

What the company does. The latest quarter extended revenue growth and kept operating margin near the recent range, with reported profit rising from the comparable base. The valuation sits around the middle of its available history and normalized earnings produce a similar valuation reading, so this is an earnings-delivery case rather than a trough-multiple case. Franchise additions, partnerships and the specialty launch create forward fuel, but management's revised specialty timetable and prior guidance reversals require a discount to aspirational targets.

🚨 What the surface reading misses. The surface reading is: June 2026 revenue was ₹240 crore. The research reads it further: Revenue was also 24.4% above June 2025, indicating that the reported scale increase was not solely sequential seasonality.

🚨 What the surface reading misses. The surface reading is: June revenue and net profit rose 24.4% and 34.2% year on year, respectively. The research reads it further: Profit grew faster than revenue in the comparable-quarter calculation, consistent with operating leverage, although this does not by itself prove a permanent margin step-up.

Lever 1 · Operating leverage — BUILDING. The active franchise base and scheduled net additions can extend pathology reach, subject to retention of newly added outlets. What proves it keeps working: Franchise-network expansion. It stops working if New additions churn faster than the planned net schedule or the next reported quarter misses the stated addition target.

Lever 12 · New product launch — BUILDING. Allergy, genomics and advanced tests are commercially live, with a multi-year portfolio-mix ambition rather than a near-term revenue promise. What proves it keeps working: Specialty diagnostics commercialization. It stops working if Physician-led specialty volumes do not become measurable while the target timetable continues to move outward.

Lever 15 · Market-share gains — BUILDING. Revenue growth has outpaced the rise in the fixed operating base, allowing profit to grow faster than sales in recent periods. What proves it keeps working: Operating leverage from pathology volumes. It stops working if Operating margin falls below the comparable-period level while revenue growth remains positive.

Lever 14 · A bigger market to sell into — BUILDING. Partnership revenue is expanding alongside insurance and healthtech integrations, giving the company a second volume route beyond franchises. What proves it keeps working: Partnership and backend diagnostics channel. It stops working if Partnership growth slows without a disclosed comparison-base or pricing explanation.

Sources: our stock research file (22 August 2026) · quarterly results through Jun 26 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Thyrocare Technologies Ltd reported ₹240 Cr of revenue in the Jun 26 quarter, +24.4% year on year. That is the 12th straight quarter of year-on-year growth. Over 10 years it has compounded at 13.1% a year. The last full year, FY26, came in at ₹829 Cr. The last four reported quarters add to ₹877 Cr.

Why this happened. The value-chain climb applies because the company is adding higher-complexity tests to an existing pathology platform. Central-lab capex is largely completed, but physician adoption and volume are the gating variables. The latest timetable widened, so specialty remains optionality rather than a base-year earnings assumption.

FY26 revenue came in at ₹829 Cr (+20.7% on the year), capping 10 years at 13.1% compound. The latest quarter (Jun 26) printed ₹240 Cr, +24.4% year on year — the 12th consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +21.2% growth against the decade's 13.1% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +21.3% over the last 4 quarters against +21.5%/yr over the last 8 — stabilising; TTM profit +67.6% vs +52.2%/yr — accelerating.

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Thyrocare Technologies Ltd's operating margin is 32.0% in the Jun 26 quarter, +2.0 percentage points against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged 23.0% to 41.0%. The current quarter sits inside that band.

Why this happened. Management reported the active franchise base at the latest quarter and set a staged plan for net additions across the year. This supports volume growth through distribution rather than a new laboratory build. The off-switch is churn among the early additions or a failure to meet the next quarterly addition target.

The latest quarter's operating margin is 32.0%, +2.0 pp against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged 23.0%–41.0%.

Why the margin moved: operating margin went +2.3 pp year on year while gross margin went +2.9 pp — the gain came mostly from the gross line: input costs and pricing.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Thyrocare Technologies Ltd earned ₹51.0 Cr of net profit in the Jun 26 quarter, +34.2% year on year. It is the 10th consecutive quarter of growth. Full-year FY26 profit was ₹163 Cr. The 10-year compound rate is 12.1%. That is 21.3% of the quarter's revenue. The same quarter a year earlier earned ₹38.0 Cr.

Jun 26 profit was ₹51.0 Cr, +34.2% year on year — the 10th consecutive quarter of growth. On the full year, FY26 printed ₹163 Cr (+79.1%), and the 10-year compound rate is 12.1%.

Why profit moved: revenue contributed +24.4% and the margin +2.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.

Pace comparison, last four quarters: profit +72.2% vs revenue +21.2%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 177% of Thyrocare Technologies Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹213 Cr of operating cash against ₹163 Cr of profit. After ₹68.0 Cr of capital spending, ₹145 Cr was left as free cash.

FY26: operating cash of ₹213 Cr against reported profit of ₹163 Cr, leaving free cash of ₹145 Cr after ₹68.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 177% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 177%: the cash cycle tightened 25 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.

Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Thyrocare Technologies Ltd's cash conversion cycle runs 4 days in FY26, down from 29 days in FY21. Capital spending ran ₹185 Cr over the last 3 years. At FY26 sales of ₹829 Cr each day of that cycle holds about ₹2.3 Cr, so roughly ₹9.0 Cr sits inside the business at any moment.

FY26: debtors at 33 days, inventory at 81 days — roughly 2.7 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 4 days, tighter than FY21's 29.

The full loop: cash goes out to suppliers and production on day 0; stock waits 81 days to sell; customers pay about 33 days after that; and suppliers themselves are paid at 109 days — netting out to the 4-day cycle.

In money terms: at FY26 sales of ₹829 Cr, each day of the cycle holds about ₹2.3 Cr — so the 4-day loop keeps roughly ₹9.0 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹185 Cr over the last 3 fiscal years against ₹161 Cr of depreciation — building somewhat ahead of wear-and-tear. Capital work-in-progress stands at ₹3.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Thyrocare Technologies Ltd earns a ROCE of 35% in FY26. That is up from a trough of 17% in FY23. Return on invested capital clears the cost of that capital by +25.9 percentage points, so growth here adds value rather than only size. The wiring behind it is 19.7% net margin on 1.11× asset turns.

FY26 ROCE is 35%, recovered from a FY23 trough of 17% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY26): 19.7% net margin × 1.11× asset turns × 1.28× balance-sheet leverage ≈ 28.0% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.

The capstone test — ROIC − WACC: 37.9% − 12.0% = a +25.9 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Thyrocare Technologies Ltd carries total debt of ₹51.0 Cr against shareholder equity of ₹586 Cr as of Mar 26, a debt-to-equity of 0.09 — effectively unlevered. On the annual view that ratio went from 0.04 in FY22 to 0.09 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.

Mar 26: total debt of ₹51.0 Cr against shareholder equity of ₹586 Cr — a debt-to-equity of 0.09. On the annual view, debt-to-equity went from 0.04 (FY22) to 0.09 (FY26). The returns on this page are earned, not borrowed.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Promoters cut 10.2 points of Thyrocare Technologies Ltd over 8 quarters, the biggest move on the register. That takes promoters to 60.9% of the company. Domestic institutions moved +6.0 points over the same window, to 20.9%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Promoters: −10.2 points over 8 quarters to 60.9%; Domestic institutions: +6.0 points over 8 quarters to 20.9%; Foreign institutions: +2.9 points over 8 quarters to 5.4%.

🚨 Why the register moved: promoters drove it (−10.2 points), absorbed on the other side by domestic institutions (+6.0 points) — distribution into the market’s bid.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Thyrocare Technologies Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Thyrocare Technologies Ltd trades at 48.4× P/E, mid-range by its own standards (54th percentile). Its long-run median P/E is 47.4×, measured across 10.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 48.4× is mid-range by its own standards (54th percentile), against a long-run median of 47.4× measured over 10.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved +77.8% against a +34.8% price move — earnings outran the price, pushing the multiple DOWN its own range.

The price move, decomposed: over 5y, of the +5.3%/yr price move, ~+1.3%/yr came from earnings growth and ~+4.0 pp from the multiple (expanding); over 10y, of the +10.3%/yr price move, ~+11.9%/yr came from earnings growth and ~−1.6 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.

Solved at its 24 August 2026 price, Thyrocare Technologies Ltd was paying for profit growth of about 26.2% a year. Profit itself has compounded 12.1% a year over the past 10 years. Today the market pays 48.4× P/E, the 54th percentile of its own 10-year range.

What the two numbers say together. The multiple is unremarkable against its own past, and the growth the price is paying for is far above what this company has actually delivered.

How to hold this number: it is a reading of one day's price, taken on 24 August 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.

Stage: Consistent Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Thyrocare Technologies Ltd reads as consistent on its fundamental arc. Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 35.8% and holding. The read is built from 12 quarters across 4 curves, on full evidence.

Why it matters: steady curves with healthy returns are the compounding setup — the risk is the price, not the business.

4-Factor Sector Score

68.3/100 — rank 2 of 9 in Diagnostics · 100% evidence confidence

Thyrocare Technologies Ltd scores 68.3 out of 100 against the 9 companies it is compared with in Diagnostics, ranking 2. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 27.9 + 18.9 + 11.2 + 10.3 = 68.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Said versus delivered

What Thyrocare Technologies Ltd's management promised, set against what actually arrived — 4 tracked promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.

Specialty Mix Timeline Widened · 23 July 2026. In the Jan 2026 and May 2026 calls, management framed specialty diagnostics as reaching a significant or peer-level mix within approximately three years. In the Jul 2026 call, management widened the timeframe to three to five years without explaining whether this reflects slower adoption, a changed investment plan, or increased uncertainty; the five-year outer bound represents a potentially material extension of the growth thesis.

Radiology Recovery Promised but Never Delivered · 12 May 2026. In Oct 2025, management explicitly committed to radiology revenue growth returning in Q3 FY26 once all centers were fully operational, characterizing the situation as a temporary operational halt. The Jan 2026 call showed radiology was still pulling consolidated growth down to 18% with no recovery evident. By May 2026, the full year showed a 6% decline in radiology revenue, and management recharacterized the episode as a deliberate strategic consolidation - a fundamentally different narrative from the specific recovery commitment made in Oct 2025, with no prior disclosure of this strategic pivot.

🚨 Tanzania Revenue Doubling Target Missed Without Acknowledgment · 12 May 2026. In Oct 2025, management set a specific expectation that Tanzania would double its revenues during FY26, implying approximately 100% growth. The May 2026 full-year results disclosed that Tanzania grew only over 75% year-on-year, materially below that stated target. Management provided no acknowledgment of this miss and no explanation for the shortfall when presenting annual results, which would concern analysts tracking management's ability to forecast its international expansion strategy.

GLP-1 Opportunity Reversal · 28 January 2026. Management previously touted the GLP-1 weight loss drug market as a huge opportunity they were well-geared for, claiming it would drive significant diagnostic testing volume. In the latest call, the CEO explicitly retracted this optimism regarding the timeline, admitting they have not seen the expected uptake and that patients have not matured to regular testing yet. Earlier call (Oct 2025): “I genuinely believe that is going to be a huge opportunity... never seen a molecule... reach INR100 crores in such a short period of time... We are also in the process of launching complementary packages... so that as you get on these weight loss drugs, you preserve your health.” Later call (Jan 2026): “I stand corrected on the timing. We haven”.

Every quote above is taken word for word from the company’s own earnings calls.

Frequently asked questions